
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
AFT Pharmaceuticals Limited is a drug manufacturers-specialty & generic business based in Australia. AFT Pharmaceuticals shares (AFP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. AFT Pharmaceuticals has a market cap (total outstanding shares value) of $406.5 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $3.1 - $5.25 |
---|---|
50-day moving average | $4.6164 |
200-day moving average | $4.6289 |
Target price | N/A |
PE ratio | 37.8627 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.1175 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing AFT Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AFT Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AFT Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, AFT Pharmaceuticals shares trade at around 38x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Gross profit TTM | $48.3 million |
---|---|
Return on assets TTM | 8.21% |
Return on equity TTM | 17.89% |
Profit margin | 3.7% |
Book value | N/A |
Market capitalisation | $406.5 million |
TTM: trailing 12 months
We're not expecting AFT Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, AFT Pharmaceuticals's shares have ranged in value from as little as $3.1 up to $5.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while AFT Pharmaceuticals's is 0.2138. This would suggest that AFT Pharmaceuticals's shares are less volatile than average (for this exchange).
AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers approximately 130 prescription and non-prescription products for use in the areas of allergy, eye care, first aid, fungal, pain management, and skin care, as well as supplements. It is also involved in the distribution of pharmaceuticals. The company was founded in 1997 and is headquartered in Auckland, New Zealand.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.
Steps to owning and managing Top Shelf International shares.
Steps to owning and managing K12 Inc shares from Australia.
Steps to owning and managing 2U Inc shares from Australia.
Steps to owning and managing Chegg Inc shares from Australia.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.